Status:
Concluded with an LOI
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Psoriatic Arthritis
Last updated December 19, 2017
Ravicti (glycerol phenylbutyrate)
Status:
Concluded with an LOI
Manufacturer:
Horizon Therapeutics Ireland DAC
Indication:
Urea cycle disorders
Last updated December 12, 2017
Status:
Concluded with an LOI
Manufacturer:
Actelion Pharmaceuticals Ltd.
Indication:
Pulmonary Arterial Hypertension
Last updated December 12, 2017
Status:
Negotiations were not pursued
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated December 8, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma
Last updated December 8, 2017
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma
Last updated December 8, 2017
Methadose (methadone hydrochloride)
Status:
Concluded without agreement
Manufacturer:
Mallinckrodt Canada ULC
Indication:
Opioid Dependence
Last updated November 30, 2017
Status:
Concluded without agreement
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Prevention of atherothrombotic events with history of myocardial infarction
Last updated November 30, 2017
Tafinlar/Mekinist (dabrafenib/trametinib)
Status:
Negotiations were not pursued
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Indication:
Non-Small Cell Lung Cancer (with CNS metastases)
Last updated November 30, 2017
Status:
Concluded with an LOI
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Severe Eosinophilic Asthma
Last updated November 24, 2017